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Abstract
Purpose of review Pluripotentstemcells (PSCs)have thecapac-
ity to differentiate into various types of cells, and are promising
cell sources for regenerative therapy and drug screening.
However, to realize theclinical applicationofPSCs, a largenum-
ber of highly qualified target cells must be stably prepared with
low cost. To achieve this, great improvements in the
reprogramming, differentiation, and elimination of residual
PSCswillbenecessary. In this review,wesummarize theupdated
knowledge about metabolism in PSCs and its application.
Recent findings Recent studies have shown that PSCs have
distinct metabolic profiles compared to differentiated cells.
The metabolic profiles of PSCs are indispensable for the
maintenance of pluripotency, self-renewal, differentiation ca-
pacity, and cell survival.
Summary Metabolic approaches show improved simplicity,
scalability, and lower cost than conventional methods for dif-
ferentiation and elimination of residual PSCs. Thus, manipu-
lation of PSC metabolism will lead to new technologies to
improve their efficiencies.
Keywords Embryonic stem cells . Induced pluripotent stem
cells . Differentiation . Purification .Metabolism .
Regenerative therapy
Introduction
Pluripotent stem cells (PSCs), including embryonic stem cells
(ESCs) [1] and induced pluripotent stem cells (iPSCs), can
theoretically self-renew infinitely [2, 3] and differentiate into
various types of cells, including cardiomyocytes, neurons, and
hepatocytes. Based on their unique characteristics, the clinical
application of PSCs such as in regenerative therapy and drug
screening for numerous diseases has been proposed.
However, for realization of their clinical application, a large
number of cells should be stably prepared without requiring
an enormous cost. There are many processes available to ob-
tain the target cells, including reprogramming, differentiation,
and elimination of residual PSCs from PSC-derived cells.
Each process has been dramatically improved in recent years
with the development of many technologies. With respect to
the reprogramming process, use of a temperature-sensitive
mutated Sendai virus with Yamanaka factors (OCT4, SOX2,
KLF4, and c-MYC) was shown to substantially improve the
efficiency of iPSC generation [4]. In addition, co-expression
of maternal-specific factors in oocytes such as GLIS1 [5],
TH2A/TH2B [6], and H1foo [7] with Yamanaka factors also
enhanced the reprogramming efficiency in iPSC generation.
With respect to pluripotency, human PSCs (hPSCs) have been
shown to be capable of switching to the naïve state by use of a
combination of small molecules, similar to mouse PSCs
(mPSCs) [8–11]. Moreover, the efficiencies of differentiation
into cardiomyocytes could be greatly improvedwith the use of
recently identified small molecules rather than recombinant
proteins [12, 13]. Furthermore, fluorescence-activated cell
sorting (FACS)-based methods or toxin-based methods have
been developed for the elimination of residual PSCs after dif-
ferentiation [14–17]. However, more improvements are re-
quired to realize the clinical application of PSCs in terms of
reducing the cost and enhancing the scalability.
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PSCs show unique metabolic features to maintain their
pluripotency and proliferative ability, and their metabolism
changes dramatically during the processes of reprogramming
and differentiation. Accordingly, methods to improve meta-
bolic regulation should be of great benefit for enhancing the
efficiencies of PSCs. Many powerful analysis tools such as
metabolomics, proteomics, and transcriptomics have been de-
veloped to obtain metabolic profiles [18–20], which can be
used to dramatically advance analyses of the metabolic fea-
tures of PSCs and differentiated cardiomyocytes. Here, we
introduce the updated knowledge about metabolism in PSCs
and manipulation of their metabolism for clinical application.
Metabolism for Self-Renewal and Pluripotency in PSCs
Metabolism in mPSCs
mPSCs have been reported to be highly dependent on glycolysis
[21, 22] (Fig. 1). Specifically, in the process of reprogramming
mouse embryonic fibroblasts intomiPSCs, the degree of depen-
dence onglycolysis greatly increases and that onoxidative phos-
phorylation (OXPHOS) decreases, similar to the high depen-
dence of mouse ESCs (mESCs) upon glycolysis. This finding
demonstrates that metabolic reprogramming also occurs during
the process of iPSC generation. Interestingly, glycolytic gene
expression was found to precede pluripotent marker induction
during reprogramming [23]. In fact, inhibition of glucosemetab-
olism decreased the reprogramming efficiency. Given the acti-
vated glycolytic features of mESCs, it is reasonable that they
would be efficiently reprogrammed under a hypoxic condition
[24]. These findings indicated that glucose metabolism plays a
key role during reprogramming. In addition, during the
reprogramming process, a transient OXPHOS burst occurs by
induction of estrogen-related nuclear receptors such as ERRα
and ERRγ and their co-factors such as PGC1α and PGC1β
[25]. By contrast, depletion of these factors reduces the
reprogramming efficiency in mouse embryonic fibroblasts
[25]. Moreover, the pentose phosphate pathway (PPP) and syn-
thesis of amino acids are also activated inmESCs because of the
need to produce nucleotides and amino acids for proliferation
[26••]. Taken together, these studies suggest that mPSCs are de-
pendent on glycolysis not only for ATP production, but also for
biomass production, including nucleotides and amino acids.
Furthermore, redox status is also important for the maintenance
in PSCs. Yanes et al. demonstrated that mESCs were character-
ized by a high reduced-to-oxidized glutathione ratio and abun-
dant metabolites with highly unsaturated structures. As a result,
inhibition of the eicosanoid signaling pathway, a well-known
pro-oxidative cascade, could promote pluripotency bymaintain-
ing the levels of unsaturated fatty acids [27•].
Pluripotency shows diverse states, and each state has dif-
ferent metabolic characteristics. mESCs are typically cultured
in medium containing serum plus leukemia inhibitory factor
(LIF), which maintains the cells in a naïve state of
pluripotency, although they can switch to activin/nodal-
dependent epiblast stem cells (EpiSCs) whose state (primed
state) is a little downstream from a naïve state. EpiSCs are
highly glycolytic and have low mitochondrial respiratory ca-
pacity compared to mESCs due to the increased expression of
hypoxia-inducible factor 1α [28] (Fig. 1). In addition, tran-
scription factor STAT3, downstream of the LIF-dependent
pathway, has been reported to increase OXPHOS in mESCs
[29]. mESCs have also been reported to reach a ground state
of pluripotency under specific conditions when cultured in
medium containing glycogen synthase kinase 3 (GSK3) and
mitogen-activated protein kinase (MAPK)/extracellular
signal-related kinase (ERK) inhibitors (2i) plus LIF [8]. As
the ground-state mESCs (cultured in 2i plus LIF) maintain a
high α-ketoglutarate (αKG) level, which is produced from
glucose and glutamine, they could readily proliferate in the
absence of glutamine. By contrast, mESCs (cultured in serum
plus LIF) could not proliferate without glutamine, because
αKG is mainly produced from glutamine [30••]. The
ground-state mESCs (cultured in 2i plus LIF) exhibited an
elevated αKG-to-succinate ratio, which promoted histone
and DNA demethylation, including histone 3 lysine 27
trimethylation (H3K27me3) and ten-eleven translocation
(Tet)-dependent DNA demethylation. Moreover, pluripotency
was maintained because αKG is a cofactor of Fe (II)- and
αKG-dependent dioxygenases, including Jumonji C
domain-containing histone demethylases and Tet. Recently,
the intracellular αKG level was reported to be affected by
phosphoserine aminotransferase 1 (PSAT1), an enzyme in-
volved in de novo serine synthesis that utilizes glutamate as
an amino group donor and produces αKG in mPSCs. In the
undifferentiated state, OCT4, SOX2, and NANOG bind to the
PSAT1 enhancer region to regulate PSAT1 expression [31•].
Moreover, mESCs are also highly dependent on threonine
catabolism, which produces glycine and acetyl-CoA via thre-
onine dehydrogenase (TDH) that are required for S-
adenosylmethionine (SAM) synthesis [32••, 33•]. As SAM
production is important for histone methylation, cell culture
in threonine-depleted conditions leads to a decrease in the
SAM level, which, in turn, reduces the degree of histone H3
lysine 4 trimethylation (H3K4me3), resulting in difficulty of
pluripotency maintenance.
Metabolism in hPSCs
hPSCs are also dependent on glycolysis for ATP generation, and
showdecreased pyruvate oxidation due to the high expression of
uncoupling protein 2 (UCP2), a mitochondrial inner membrane
protein [34]. hPSCs also highly consume several amino acids,
including glutamine and methionine. We demonstrated that glu-
tamineoxidationwas indispensable forATPgeneration inhPSCs,
and glutamine metabolism was more strongly activated under
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glucose-depleted conditions [35•] (Fig. 1). In addition, glutamine
metabolism contributes to reduced GSH synthesis. GSH is not
only essential to maintain the redox state but also prevents the
degradationofOCT4 [36].UnlikemPSCs, hPSCs are not depen-
dent on threonine catabolism, because the human TDH gene is a
nonfunctional pseudogene and threonine cannot contribute to
SAMproduction. Instead, hPSCs depend onmethionine catabo-
lism for SAMproduction [37•].Moreover, hPSCs utilize glucose
for the production of cytosolic acetyl-CoA, which promotes his-
toneacetylation in apluripotent state [38•].Recently, hPSCswere
reported to be able switch to a naïve state by use of a combination
of small molecules such as GSK3 inhibitor (CHIR99021),
MAPK/ERKkinase (MEK) inhibitor (PD0325901), c-JunN-ter-
minal kinase (JNK) inhibitor (SP600125), p38 inhibitor
(BIRB796), human LIF, insulin-like growth factor (IGF), and
basic fibroblast growth factor (bFGF) [9–11]. Sperber et al. dem-
onstrated that nicotinamide N-methyltransferase (NNMT) was
upregulated in naïve hPSCs [39]. In naïve hPSCs, NNMT con-
sumesSAM,which leads tomaintenance of lowSAMlevels and
the H3K27me3-repressive state.
Manipulation of Pluripotent Stem Cell Metabolism
Glucose, glutamine, and methionine metabolism are indis-
pensable for the self-renewal, pluripotency, and survival of
PSCs in terms of their contributions to energetics, epigenetics,
and redox status. Therefore, it follows that manipulation of
glucose, glutamine, and methionine metabolism can be used
to regulate the differentiation efficiency and survival of PSCs.
Differentiation and Metabolism
Several studies have demonstrated the essential roles of cellular
metabolism during the differentiation of PSCs. Upon differenti-
ation, PSCs show reduced reliance on glycolysis and increased
mitochondrial numbers and maturation [40], leading to repres-
sion of UCP2 expression and a consequent increase in oxidative
phosphorylation and reactive oxygen species (ROS) generation
[41, 42]. It is well known that ROS enhance the differentiation
efficiency of hESCs into cardiomyocytes via activation of p38
MAPK and/or phosphoinositol 3-kinase [43, 44]. A supra-
physiological concentration of glucose in the culture medium
was shown to result in increased ROS production, leading to
enhanced cardiomyocyte differentiation [45]. Intriguingly, sup-
plementation of hydrogen peroxide was shown to improve
cardiogenesis in low glucose conditions. These findings were
also supported by the fact that mESCs show abundant intracel-
lular polyunsaturated fatty acids,which decrease after differenti-
ation. As the ROS level is increased during differentiation, un-
saturated fatty acids are oxidized, leading to an increased
Fig. 1 Metabolic features in PSCs and differentiated cardiomyocytes.
Naïve-state PSCs like mESCs depend on glucose and glutamine
metabolism. Glucose or glutamine-derived αKG is important for
histone and DNA demethylation related with pluripotency. Primed-state
PSCs like hPSCs highly depend on glycolysis compared to naïve-state
PSCs due to higher HIF1α expression. In addition, hPSCs also depend on
glutamine oxidation not only for ATP production but also for glutathione
(GSH) production. High GSH production is important for maintenance of
pluripotency because glutamine-derived GSH plays as a scavenger for
ROS and prevents OCT4 degradation. Moreover, glucose-mediated
cytosolic acetyl-coenzyme A (CoA) contributes to histone acetylation
for pluripotency as well as to lipid synthesis for proliferation, while
threonine- or methionine-derived SAM also contributes to histone
H3K4me3, which is also important for the maintenance of pluripotency
in PSCs. In contrast to PSCs, differentiated cardiomyocytes can utilize
pyruvate or lactate efficiently for ATP production and GSH synthesis.
PPP pentose phosphate pathway; NNMT nicotinamide N-
me thy l t r an s f e r a se ; GSH reduced g lu t a th ione ; SAM S-
adenosylmethionine; ROS reactive oxygen species
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eicosanoidlevel.Therefore, itsdownstreamoxidizedmetabolites
such as palmitic acid, capric acid, and palmitoyl carnitine pro-
mote the differentiation of mESCs into neurons or
cardiomyocytes [27•]. In addition, supplementation of ascorbic
acid could enhance cardiomyocyte differentiation from PSCs
[46, 47]. Although ascorbic acid is known for its antioxidant
property, other antioxidants such as N-acetylcysteine or vitamin
E failed to recapitulate the observed positive effects of ascorbic
acid on differentiation. Ascorbic acid was also reported to pro-
mote cardiogenesis via induction of the proliferation of cardiac
progenitor cells through increased collagen synthesis via the
MEK-ERK1/2 pathway [46, 48]. Togetherwith the findings that
ROS enhance the PSC differentiation efficiency, these results
suggest that ascorbic acidmight have a specific effect other than
modulation of the redox status [47].
Decreased glycolysis was shown to reduce the levels of cyto-
solic acetyl-CoA, which is utilized for histone acetylation. The
need for the reduction of acetyl-CoA in differentiation was con-
firmed by supplementation of its precursor acetate, which blocks
early histone deacetylation and delayed differentiation [38•]. In
addition, although ahighαKGlevel is important formaintenance
of pluripotency via histone and DNA demethylation in mPSCs,
the intracellularαKG level was shown to decline transiently dur-
ingdifferentiation,whereasαKGsupplementationdelayeddiffer-
entiation in mPSCs [31•]. By contrast, TeSlaa et al. reported that
αKG supplementation promoted the early differentiation of
hPSCs, while accumulation of succinate delayed differentiation
[49•].Moreover, another group demonstrated that glutamine dep-
rivation led to differentiation into endothelial cells from hPSCs
because glutamine-derivedGSH is essential to prevent the degra-
dationofOCT4[36].Theinterpretationof thesefindingsinhPSCs
is slightly complicated, because in somecases, glutamine-derived
αKG promoted differentiation, whereas in other cases, it was de-
layed.Hence, further studies are needed to clarify the relationship
between differentiation and glutamine metabolism. However, in
human hematopoietic stem cells, glucose and glutaminemetabo-
lismareknowntobeessential forerythroiddifferentiation through
de novo nucleotides synthesis. Blocking glucose and glutamine
metabolism or nucleotides synthesis inhibited erythroid commit-
ment, even in thepresenceoferythropoietin,becauseof the lackof
nucleotides [50•]. Furthermore, methionine affects the epigenetic
status in hPSCs via SAM production, as described above. Thus,
exposure to methionine deprivation could rapidly reduce the in-
tracellular SAM level, leading to the reduction of H3K4me3 and
DNAmethylation, followedbyactivationofp53-38signalingand
suppressionofNANOGexpression [37•]. Indeed, short-termme-
thionine deprivation resulted in the promotion of differentiation
into all three germ layers.
Elimination of Residual PSCs
Despite great improvements in methods for achieving the dif-
ferentiation of PSCs to target cells, it is nearly impossible to
ensure that all iPSCs can differentiate into target cells.
Accordingly, a given population of PSC-derived cells gener-
ally contains residual undifferentiated PSCs, which are the
main contributors to tumor formation. The risk of tumor for-
mation was reported to be higher with a contamination rate of
residual PSCs of more than 0.02% in PSC-derived cells [51,
52]. Therefore, to improve the safety of PSC-based applica-
tions, many methods have been developed to eliminate these
residual PSCs. Cell sorting is one such method, in which plu-
ripotent markers such as TRA1-60, SSEA-4, or SSEA-5 are
used [17]. Although these strategies are simple, the methods
are not suitable for large-scale culture because use of FACS is
a time-consuming process. Alternatively, a metabolism-based
approach is thought to be ideal for large-scale culture in terms
of its simplicity, scalability, and low cost. To efficiently elim-
inate residual PSCs, it is necessary to understand and facilitate
the metabolic characteristics of PSCs. As described above,
PSCs have an activated glycolysis and PPP. Therefore, by
utilizing these characteristics, it is natural that glucose deple-
tion from the culture media will effectively eliminate residual
PSCs [26••, 53]. In addition, our group demonstrated that
glutamine metabolism contributes not only to nucleotides
and GSH synthesis but also to ATP generation [35•].
Consequently, we showed that glucose- and glutamine-
depleted conditions efficiently eliminated residual PSCs for
short periods [35•]. Moreover, since hPSCs depend on methi-
onine catabolism for SAM production, prolonged methionine
deprivation induced the apoptosis of hPSCs via activation of
the p53-p38 cell apoptosis signaling pathway [37•]. However,
these specific conditions may affect the target cells if PSCs are
cultured under the conditions for long periods, because such
conditions are based on the deprivation of essential metabo-
lites for PSCs. Therefore, other alternative metabolites should
be applied to minimize the negative effects.
Metabolic Selection of Differentiated Cardiomyocytes
To identify alternative metabolites for target cells, it is neces-
sary to first understand their metabolism. For example, our
group focused on PSC-derived differentiated cardiomyocytes
that displayed a fetal phenotype. In the fetal heart, glucose and
lactate are the major energy substrates because the concentra-
tions of both glucose and lactate are high in the fetal circula-
tion [54, 55]. Therefore, we hypothesized that lactate would
be an alternative energy source under glucose-depleted condi-
tions for PSC-derived cardiomyocytes. In fact, the PSCs could
efficiently utilize lactate for ATP generation [26••]. Moreover,
lactate was also found to contribute to glutamate and gluta-
mine synthesis under glutamine-depleted conditions [35•].
Interestingly, hPSCs cannot efficiently utilize pyruvate or lac-
tate due to the poor expression of metabolic enzymes such as
aconitase 2 and isocitrate dehydrogenase 2/3, in contrast to
differentiated cardiomyocytes [35•] (Fig. 1). Furthermore,
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most of the hPSC-derived non-cardiac cells remaining after
differentiation also depend on glucose and/or glutamine and
show difficulty in the utilization of lactate [35•]. As a result,
we succeeded in purifying only differentiated cardiomyocytes
by cultivation under glucose- and glutamine-depleted condi-
tions with lactate supplementation. After purification, contam-
ination of residual PSCs was lower than 0.001%. Therefore,
metabolically selected cardiomyocytes derived from hPSCs
appear to be safer for transplantation. To date, the strategies
developed for the purification of cardiomyocytes have been
based on a combination of FACS and the use of antibodies or
mitochondrial dye [40, 56]. Therefore, adoption of a metabol-
ic approach will represent a breakthrough in the large-scale
production of hundreds of millions of cardiomyocytes for
transplantation without requiring an enormous cost.
Conclusions
Metabolism plays many roles in the reprogramming,
pluripotency, self-renewal, differentiation, and survival of PSCs
in terms of regulating their energetics, epigenetics, and redox
status.Therefore, understanding andmanipulating themetabolic
regulationmechanismsofPSCs shouldprove tobe auseful strat-
egy for enhancing their beneficial properties and safety for clin-
icalapplication. Indeed,emergingevidenceshowsthatmetabolic
regulation by supplementation of certain metabolites or com-
pounds can delay or promote differentiation. Moreover, the use
of specific culture conditions can selectively eliminate residual
undifferentiated PSCs and purify the differentiated
cardiomyocytes. As described above, metabolic approaches
have several advantages over conventional methods for PSC
reprogramming and differentiation, including their simplicity,
scalability, and low cost. Our group has already successfully
established large-scale culturemethods to obtain a large number
ofmetabolically selected cardiomyocyteswith low cost (unpub-
lished). Themain challenge in this field at present is to develop a
comprehensive understanding of themetabolic profiles in PSCs,
whichwill certainly lead to thedevelopmentofnew technologies
to efficiently produce a large number of target cells for clinical
application.
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